Inflammatory Bowel Disease
Conditions
Interventions
control group:placebo
experimental group:Bifidobacterium-Lactobacillus Triple Live Bacteria
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
15 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Definitive diagnosis of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), based on comprehensive analysis. (2) Aged 15 to 80 years, regardless of gender. (3) Voluntary participation in the study and signing of a written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with Crohn's disease (CD) having a Best CDAI score > 450, or patients with ulcerative colitis (UC) having a modified Mayo score > 10. (2) Those who refuse to sign the informed consent form. (3) Those who have used antibiotics, probiotics, prebiotics, or other drugs that may affect intestinal microecology within the past 2 weeks. (4) Those with severe diseases such as diabetes mellitus, thyroid dysfunction, severe hepatic or renal insufficiency, cardio-cerebrovascular diseases, or malignant tumors, which may interfere with the assessment of study results. (5) Those with gastric cancer, peptic ulcer, intestinal cancer, dysplasia, or other organic gastrointestinal diseases detected by gastroenteroscopy within the past year. (6) A history of abdominal surgery (excluding appendectomy and cesarean section). (7) A known history of allergy to fluorescein or severe allergic reactions (e.g., laryngeal edema, anaphylactic shock) following previous injections. (8) A history of asthma, or allergies to cephalosporins or penicillins. (9) Patients receiving concurrent ß-blocker therapy (intravenous fluorescein administration is relatively contraindicated in patients on ß-blockers according to the statement of the German Federal Institute for Drugs and Medical Devices). (10) Patients taking antihypertensive drugs, or those with hypotension or bradycardia. (11) Those who have recently taken nephrotoxic drugs (e.g., aminoglycoside antibiotics). (12) Pregnant or lactating women, or those planning to become pregnant within the next 3 months. (13) Patients with mental illness or cognitive impairment who are unable to cooperate with the study procedures. (14) Patients deemed unsuitable for participation in this clinical trial by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The cure rate of SIBO/IMO in IBD patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intestinal mucosal barrier indicators;Intestinal microbiota;Oral microbiota; | — |
Countries
China
Contacts
Public ContactLing Liu
West China Hospital, Sichuan University
Outcome results
None listed